Gain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, “SEE-Tx™,” is a novel approach that uses structural and computational biology to discover previously unidentified allosteric binding sites with high potential for druggability. These sites can be targeted with small molecules for therapeutic benefit to correct enzyme misfolding, thereby restoring function, eliminating toxic substrate, and addressing the underlying cause of disease. SEE-Tx™ is an entirely new drug discovery and development process made possible by Supercomputing with the potential to transform this process into a more efficient method with life changing treatments created in a fraction of the time at a fraction of the cost and for multiple disease target. The platform has generated all of the development candidates currently in Gain’s pipeline. Gain has an initial focus in lysosomal storage diseases and CNS disorders, but the platform is agnostic and can be applied to any disease caused by protein misfolding, including the disease areas of metabolism, immunology, and oncology. The company has an experienced and highly successful Board of Directors and management team with over $30 billion in transactional history.